BSECompany Update3d ago
SUDARSHAN PHARMA INDUSTRIES LIMITED
SUDARSHAN PHARMA INDUSTRIES LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left" > </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Sudarshan Pharma Industries Limited has informed BSE about the cessation of Company Secretary and Compliance Officer - XBRL.
BSECompany UpdateMgmt Change3d ago
SUDARSHAN PHARMA INDUSTRIES LIMITED
SUDARSHAN PHARMA INDUSTRIES LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left" > </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Sudarshan Pharma Industries Limited has informed BSE about the cessation of its Company Secretary and Compliance Officer.
BSECompany Update3d ago
SUDARSHAN PHARMA INDUSTRIES LIMITED
SUDARSHAN PHARMA INDUSTRIES LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left" > </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Sudarshan Pharma Industries Limited has informed the BSE about the cessation of its Company Secretary and Compliance Officer.
BSECompany Update3d ago
SUDARSHAN PHARMA INDUSTRIES LIMITED
SUDARSHAN PHARMA INDUSTRIES LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left" > </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Sudarshan Pharma Industries Limited has informed the BSE about the cessation of its Company Secretary and Compliance Officer.
BSECompany UpdateMgmt Change3d ago
Sudarshan Pharma Industries Ltd
Pursuant to Regulation 30 and other applicable Regulations, if any, of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (''SEBI Listing Regulations''), we inform you that Mr. Nirav Shah has resigned as the Company Secretary and Compliance Officer of the Company with effect from 9/Nov/2026.
Sudarshan Pharma Industries Ltd announced the resignation of Mr. Nirav Shah as Company Secretary and Compliance Officer, effective November 9, 2026, due to personal and professional reasons.
BSECompany UpdateResults5d ago
Sudarshan Pharma Industries Ltd
In terms of Regulation 30 read with Para A of Part A of Schedule III to the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby submit the updated Investor Presentation.
Request you to take the same on your record.
Sudarshan Pharma Industries Ltd submitted an updated Investor Presentation as per Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
BSECompany UpdateFundraise30 Oct 2026
Sudarshan Pharma Industries Ltd
In continuation of the Company''s letter dated 30/Oct/2026 (ref. no. SPIL/CS/2026-2027/72), the Board of Directors at its Meeting held on 29/Oct/2026 have approved the proposal to raising of funds through issue and allotment of Convertible Warrants upto an amount not exceeding Rs.72 Crores, each warrant convertible into 1 equity share of Re1/- each, on a preferential basis to Mr. Hemal Mehta and Mr. Sachin Mehta, Promoters of the Company.
The ....
Sudarshan Pharma Industries Ltd has approved a proposal to raise funds through the issue and allotment of Convertible Warrants worth up to Rs.72 Crores to its promoters, Mr. Hemal Mehta and Mr. Sachin Mehta, on a preferential basis.
BSECompany UpdateFundraise30 Oct 2026
Sudarshan Pharma Industries Ltd
This is to inform you that the Board of Directors of the Company at its Board Meeting held on 29/Oct/2026 has approved the proposal to raising funds through issue and allotment of up to 72 Crores Warrants, each Warrant convertible into 1 Equity Share of the face value of Re.1/- each on a preferential basis to Mr. Hemal Mehta and Mr. Sachin Mehta, Promoters of the Company.
Sudarshan Pharma Industries Ltd has approved a proposal to raise up to 72 Crores through the issue and allotment of warrants convertible into equity shares to its promoters, Mr. Hemal Mehta and Mr. Sachin Mehta, subject to regulatory and shareholder approvals.
BSEResultResults29 Oct 2026
Sudarshan Pharma Industries Ltd
We are submitting the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/Sep/2026
Sudarshan Pharma Industries Ltd has submitted its unaudited standalone and consolidated financial results for the quarter ended 30th September 2026. The results show a total income of ₹2,686.17 crore, expenses of ₹19,592.82 crore, and a profit before exceptional items and tax of ₹1,093.35 crore. The company's basic EPS is ₹0.33 and diluted EPS is ₹0.90.
BSEBoard MeetingResults26 Oct 2026
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve i) Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30-Sep-2026;
ii) consider and approve proposal for raising of funds and other ancillary functions, subject to such statutory and regulatory approvals as may be necessary.
Sudarshan Pharma Industries Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended 30-Sep-2026, and to consider and approve a proposal for raising of funds through private placement or preferential issue.
BSECompany UpdateExpansion23 Oct 2026
Sudarshan Pharma Industries Ltd
We are pleased to inform you that the Company ahs received letter from National Stock Exchange of India Limited dated 23-Oct-2026 stating that the equity shares of the Company shall be listed and admitted to dealings on the Exchange (Capital Market segment) w.e.f. 27-Oct-2026 pursuant to migration from SME platform of BSE Limited.
Sudarshan Pharma Industries Ltd has received a letter from the National Stock Exchange of India stating that its equity shares will be listed and admitted to dealings on the Capital Market Segment of the exchange from October 27, 2026, following its migration from the SME platform of BSE.
BSECompany UpdateOrder Cancel7 Oct 2026
Sudarshan Pharma Industries Ltd
In continuation of the Company''s letters dated 05/Sep/2026 and 15/Sep/2026, this is to inform you that the proposal to acquire 9.50% equity shares of common stock of Med Therapy Biotechnology Inc., USA stands terminated.
The proposal to acquire 1.50% each of the equity shares of common stock of Med Therapy by Mr. Hemal Mehta and Mr. Sachin Mehta, Promoters of the Company also stands terminated.
Sudarshan Pharma Industries Ltd has terminated its proposal to acquire 9.50% equity shares of Med Therapy Biotechnology Inc. and also terminated the proposal to acquire 1.50% each of the equity shares by its promoters, Mr. Hemal Mehta and Mr. Sachin Mehta.
BSECompany Update7 Oct 2026
Sudarshan Pharma Industries Ltd
Please find attached copy of certificates under Regulation 74(5) of SEBI ( Depository And Participants ) Regulations, 2018, received from Kfin Technologies Limited for the quarter ended 30/September/2026.
Sudarshan Pharma Industries Ltd has submitted certificates under Regulation 74(5) of SEBI (Depositories and participants) Regulations 2018 for the quarter ended September 30, 2026, to the BSE and NSDL.
BSEInsider Trading / SASTResults30 Sept 2026
Sudarshan Pharma Industries Ltd
The Trading Window of the Company shall remain closed with effect from October 1,2026 until the expiry of 48 hours after the declaration of financial results for the quarter and half year ended 30/Sept/2026.
Sudarshan Pharma Industries Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the declaration of financial results for the quarter and half year ended September 30, 2026.
BSECompany UpdateDivestiture28 Sept 2026
Sudarshan Pharma Industries Ltd
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in conitinuation of the Company''s letter dated 13/Aug/2026 regarding stake sale of 51% of the paid up capital of Ishwari Healthcare Private Limited, unlisted subsidiary of the Company, this is to inform you that the Company has completed sale of 209,100 equity shares of Rs.10/- each held by the Company.
Consequent to the aforesaid sale, ....
Sudarshan Pharma Industries Ltd has completed the sale of 51% stake in its unlisted subsidiary Ishwari Healthcare Private Limited to Mr. Amit Lalit Mehta for Rs 1.40 Crores.
BSEAGM/EGM22 Sept 2026
Sudarshan Pharma Industries Ltd
Please find enclosed the Scrutinizer''s Report on the business transacted at the 18th Annual General Meeting of the company held on Tuesday 22/SEPT/2026 through video conferencing / other audio-visual means.
Sudarshan Pharma Industries Ltd has announced the Scrutinizer's Report on the business transacted at the 18th Annual General Meeting held on September 22, 2026, through video conferencing. The report confirms the voting results for the resolutions set forth in the Notice of AGM.
BSEAGM/EGMResults22 Sept 2026
Sudarshan Pharma Industries Ltd
Please find enclosed the voting results on the business transacted at the 18th Annual General Meeting of the company held on Tuesday 22/SEPT/2026 at 3:00 p.m. through Video Conferencing/ Other Audio Visual Means.
Sudarshan Pharma Industries Ltd has announced the voting results of its 18th Annual General Meeting held on September 22, 2026, through video conferencing. The meeting was conducted in accordance with Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
BSEAGM/EGM22 Sept 2026
Sudarshan Pharma Industries Ltd
Pursuant to Regulation 30 of SEBI ( Listing Obligations and Disclosure Requirements ) Regulations, 2015 we enclose herewith the summary of proceedings of the AGM.
Sudarshan Pharma Industries Ltd held its 18th Annual General Meeting on September 22, 2026, through video conferencing. The meeting was chaired by Mr. Hemal V. Lele, Chairman & Managing Director, and discussed the company's financial performance, expansion strategy, and other operations.
BSEInsider Trading / SASTRelated Party9 Sept 2026
Sudarshan Pharma Industries Ltd
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 09, 2026 for Hemal V Mehta HUF, Mrs. Devangi Hemal Mehta, Sachin V Mehta HUF and Mrs. Namrata Sachin Mehta
Sudarshan Pharma Industries Ltd has received revised disclosures under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Hemal V Mehta HUF, Mrs. Devangi Hemal Mehta, Sachin V Mehta HUF and Mrs. Namrata Sachin Mehta.
BSEInsider Trading / SASTPledge9 Sept 2026
Sudarshan Pharma Industries Ltd
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 09, 2026 for Hemal Vasantrai Mehta
Sudarshan Pharma Industries Ltd has submitted a revised disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the release of pledge of 20,00,000 equity shares held by Mr. Hemal Vasantrai Mehta, a promoter of the company.